Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (February 2016)
17 slides from Cogstate's shareholder meeting presentation, Feb 11, 2016
Slide 1: CEO Operational Report
CEO Operational Report Annual General Meeting 23 October 2013
Slide 2: Leading the Field
Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM™ Playing an integral role Cutting edge tools to Accepted and used Giving GPs tools for in cognition-related assess, monitor and globally in critical accurate, easy clinical trials improve the athletic studies of brain measurem
Slide 3: Clinical Trials
Clinical Trials • Cogstate pays an integral role in the global undertaking of cognitive-related clinical trials with 7 out of 10 major pharma companies using Cogstate Test. • FDA Guidance recommends Alzheimer's drug makers should not rely on biomarker data alone to demonstrate effectiveness and that
Slide 4: Axon Sports
Axon Sports • Elite training systems installed at Human Performance Labs, Training Centres and college/professional team facilities throughout the USA and in the UK. • Provide college and professional athletes advanced cognitive training tools and technology as part of a program for cognitive skill
Slide 5: Cogstate Research
Cogstate Research • Cogstate developed a global reputation for engaging in world class research; – Psychological and neuropsychological – Genetic and medical conditions • Wealth of research studies involving Cogstate and the important role that research plays across the business has led to the creat
Slide 6: Accepted & used in critical studies
Accepted & used in critical studies AIBL (Australian Imaging Anti-Amyloid Treatment in Biomarkers & Lifestyle) Asymptomatic AD (A4) Critical prospective studies Dominantly Inherited have all selected Brigham Nurses Health Study Alzheimer’s Network Trials Cogstate as the – Boston Unit (DIAN-TU) partn
Slide 7: Cogstate Research use in critical Alzheimer's disease studies
Cogstate Research use in critical Alzheimer’s disease studies • Adoption of Cogstate technology by leading international Alzheimer’s disease researchers. • Cogstate selected to participate in worldwide clinical trials investigating early detection of Alzheimer’s - A4 and DIAN trial. • These are the
Slide 8: Healthcare
Healthcare • First primary care application of Cogstate technology; an important new tool to assist physicians to evaluate and monitor the cognitive function of the patient over time. • Pilot launched in Canada to GPs by Merck Canada in March 2013. • Over 450 physicians registered; 20 testing centre
Slide 9: Testing centres established
Testing centres established • Canada’s largest provider of home and community health care services; 50 home care offices, 20 community care clinics and 8,000 employees. – 20 sites live today • Testing in larger clinics and specialist centres launched in October 2013 after clearance by Health Canada.
Slide 10: Reimbursement
Reimbursement • Cash payment (in place). • Private reimbursement (available); – Available via Health Spending Account – Create demand for reimbursement from other payers • Public reimbursement (will take time); Example of cash payment – Critical to show reduced cost because of use of working: COGNIG
Slide 11: Specialists support and advocacy
Specialists support and advocacy • Advisory board of Canadian Key Opinion Leaders established. • User guide for doctors; – Everything you need to know about the product; history, validation, indications and how to interpret results. • Consultation with Canadian KOLs by Cogstate scientists providing
Slide 12: Multi-channel marketing campaign
Multi-channel marketing campaign Email campaign to 30,000 Canadian physicians • Drive awareness • Invitation to events : Paul Maruff presentation of data from AAIC • Educational material
Slide 13: FY13 Financial Results
FY13 Financial Results Revenue $12.46m, 4% Clinical Trials Net Loss $2.12m • Revenue of $11.6m. • Organic growth from larger, later stage contracts and entry into new disease areas. Healthcare • COGNIGRAM test launched in Canada to GPs accounting for major investment of capital. Sports • $0.6m reven
Slide 14: New phase in the evolution of Cogstate
New phase in the evolution of Cogstate • New revenue streams in FY13 marks the beginning of new and significant commercial opportunities: – AD testing a $500m pa global market opportunity; Cogstate has an exceptional opportunity to – Cogstate uniquely positioned to capture this market; expand its pr
Slide 15: FY14 Business Outlook
FY14 Business Outlook $2.7m of sales revenue (which was largely milestone based revenue from contracts on hand) producing cash receipts of $3.7m. Net operating cash outflow of $0.5m for the quarter. Total net cash outflow of $0.24m for the quarter. 1st Quarter Results Cash reserves at 30 Sep 2013 :
Slide 16: FY14 Business Outlook
FY14 Business Outlook Clinical Trials sales are inherently inconsistent and the quantity of sales contracts signed during Q1 was disappointing. However outstanding sales proposals are higher than the previous year. Clinical Trial FY14 revenue will be dependent upon the ability to sign new sales stil
Slide 17: Cogstate: Assess, Monitor, Improve
COGSTA’lhe ASSESS + MONITOR « IMPROVE